326 related articles for article (PubMed ID: 33006479)
21. Pembrolizumab in classical Hodgkin's lymphoma.
Maly J; Alinari L
Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R; Zinzani PL; Lee HJ; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Lin J; Kim E; Nahar A; Balakumaran A; Moskowitz CH
Blood; 2019 Oct; 134(14):1144-1153. PubMed ID: 31409671
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
Sheikh S; Kuruvilla J
Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
[No Abstract] [Full Text] [Related]
24. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
25. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
[TBL] [Abstract][Full Text] [Related]
26. Tislelizumab for the treatment of classical Hodgkin's lymphoma.
Chen J; Zhang H; Zhu L; Zhao Y; Ding Y; Yuan Y
Drugs Today (Barc); 2020 Dec; 56(12):781-785. PubMed ID: 33332484
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab for the first-line treatment of non-small cell lung cancer.
Ninomiya K; Hotta K
Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786
[TBL] [Abstract][Full Text] [Related]
28. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
29. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M; Chen L; Godfrey J; Song J; Egelston C; Puverel S; Budde LE; Armenian S; Nikolaenko L; Nwangwu M; Guo W; Gao L; Lee P; Chen R; Daniels S; Kennedy N; Peters L; Zain J; Rosen S; Forman S; Popplewell L; Kwak L; Herrera AF
Blood; 2023 Oct; 142(16):1359-1370. PubMed ID: 37339586
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibition in classical hodgkin lymphoma.
Pezeshki PS; Eskian M; Hamblin MR; Rezaei N
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1003-1016. PubMed ID: 33857395
[No Abstract] [Full Text] [Related]
31. Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Zhang XY; Collins GP
Curr Oncol Rep; 2022 Nov; 24(11):1477-1488. PubMed ID: 35696020
[TBL] [Abstract][Full Text] [Related]
32. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF; Burton C; Radford J; Miall F; Townsend W; Santoro A; Zinzani PL; Lewis D; Fowst C; Brar S; Huang B; Thall A; Collins GP
Blood Adv; 2021 Sep; 5(17):3387-3396. PubMed ID: 34477818
[TBL] [Abstract][Full Text] [Related]
33. Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review.
Ito A; Kim SW; Fukuda T
Int J Hematol; 2022 Sep; 116(3):309-314. PubMed ID: 35653054
[TBL] [Abstract][Full Text] [Related]
34. Synchronizing the use of allogeneic hematopoietic cell transplantation in checkpoint blockade therapy for Hodgkin lymphoma.
Mussetti A; Bosch Vilaseca A; Parody R; Paviglianiti A; Domingo-Domenech E; Sureda AM
Expert Rev Hematol; 2021 Sep; 14(9):809-818. PubMed ID: 34369849
[TBL] [Abstract][Full Text] [Related]
35. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
[TBL] [Abstract][Full Text] [Related]
36. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Khan N; Moskowitz AJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
[TBL] [Abstract][Full Text] [Related]
37. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy.
Maaroufi M
Crit Rev Oncol Hematol; 2023 Feb; 182():103923. PubMed ID: 36702422
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
Vassilakopoulos TP; Chatzidimitriou C; Asimakopoulos JV; Arapaki M; Tzoras E; Angelopoulou MK; Konstantopoulos K
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31362369
[TBL] [Abstract][Full Text] [Related]
40. Incorporating novel agents into frontline treatment of Hodgkin lymphoma.
Kambhampati S; Herrera AF
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):706-716. PubMed ID: 36485085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
